|
|
Oncogenomics: The Future of Cancer CarePublished by: CHI Insight Pharma Reports Published: Feb. 1, 2006 - 166 Pages Table of ContentsChapter 1. Cancer as a Genetic Disease 1.1. The Genetic Basis of Cancer Cancer Epigenetics 1.2. Cancer Statistics: Mortality Has Decreased, but the Number of New Cases Is Increasing Cancer Survivor Care 1.3. What Are Molecularly Targeted Drugs? 1.4. Target Selection versus Patient Selection 1.5. The Future of Cancer Care Parallels between Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome and Cancer Care 1.6. The Diagnostic Potential of Druggable Targets Chapter 2. Targeted Therapies: Early Success Stories and Promising Candidates 2.1. Small Molecule Drugs Gleevec (Imatinib): Approved 2001 Iressa (Gefitinib): Approved May 2003 Tarceva (Erlotinib): Approved November 2004 Promising Small Molecule Drugs in Development 2.2. Hypomethylating Agents Azacitidine Decitabine and Zebularine 2.3. Immunotherapeutic Intervention: Antibodies and Vaccines Therapeutic Monoclonal Antibodies Rituxan (Rituximab) Herceptin (Trastuzumab) Immunoconjugates Avastin (Bevacizumab) Cancer Vaccines Chapter 3. Toward Targeted Therapies: Preclinical Discovery Technology 3.1. Finding the Cancer Gene: Discovery Technology Comparative Genomic Hybridization (CGH) Array CGH 3.2. The Human Genome Project Advances in Sequencing Technology: Digital Karyotyping as an Example Accelerated Drug Discovery 3.3. Oncogenomic Diagnostic Testing: Gene Expression Technology Transcription Profiling Technology Oncogenomics Normal Tissue Database 3.4. Proteomics and Cancer Care 3.5. Preclinical Validation: Screening Cancer Genes Chapter 4. Patient-Selected Targeted Drugs in the Clinic: Opportunities and Challenges 4.1. The Gleevec Paradigm: From Skepticism to Iressa 4.2. The Importance of Patient Selection: A Scientific Argument 4.3. The Small-Size Advantage of Patient-Selected Trials 4.4. How to Design Patient-Selected Clinical Trials 4.5. Sample Acquisition as a Major Barrier to Patient-Selected Research 4.6. Lessons about Sample Acquisition from Past Attempts to Individualize Cancer Chemotherapy 4.7. Patient Selection from the Patient, Physician, and Payer Perspective: Disincentives Chapter 5. The Business of Oncogenomics: Challenges and Opportunities 5.1. Public and Academic Involvement in Translational Research Drug Discovery 5.2. The Potential Financial Rewards of a Patient-Selected Tiered Market Expanding Indications for Targeted Drugs Drug Safety The Scientific Counterargument 5.3. The Molecular Diagnostics Industry Patient-Selected Molecular Diagnostics Chapter 6. Expert Interviews Charles Brenner, PhD, Dartmouth Medical School; Coeditor (with David Duggan), Oncogenomics: Molecular Approaches to Cancer Walter P. Carney, PhD, Oncogene Science (part of Bayer HealthCare) Nicholas C. Dracopoli, PhD, Vice President of Clinical Discovery Technology, Pharmaceutical Research Institute, Bristol-Myers Squibb Geoffrey Duyk, MD, PhD, Managing Director, Texas Pacific Group Ventures Michael L. Salgaller, PhD, Toucan Capital Corporation Herman Spolders, PhD, Chief Executive Officer, OncoMethylome Sciences Chapter 7. Company Profiles Abgenix, Inc. ArtisOptimus, Inc. Dendreon Corporation Genomic Health, Inc. ImClone Systems, Inc. Medarex, Inc. OncoMethylome Sciences, Inc. Onyx Pharmaceuticals, Inc. OSI Pharmaceuticals, Inc. Spectral Genomics, Inc. Vivo Biosciences, Inc. Notes Glossary Index AbstractThe emergence of oncogenomics promises a new era of cancer care. Over the next decade or so, biomedical researchers hope to have fully catalogued all genetic alterations associated with cancer, greatly expanding the number of “druggable” anticancer molecular targets. Oncogenomics: The Future of Cancer Care analyzes the key advances and challenges associated with translating these efforts into successful, clinically meaningful therapeutic products.Oncogenomics has already seen clinical and market success with a handful of “first-generation” oncogenomic therapeutics such as Herceptin, raising hope and expectations that safer and more effective patient-selected targeted therapeutics will revolutionize cancer therapy and transform cancer into a manageable chronic disease. While patient-selected genomic-based therapy has only recently emerged as a viable clinical practice, many experts argue that it will become crucial not just in clinical practice but as an integral component of targeted drug development. However, despite the early success stories of Herceptin and Gleevec, many leaders in the field are cautious about the extent to which genomics will truly impact cancer care over the next 10 to 15 years. Employing the right tools, technologies, and strategies will be crucial to realizing the clinical and marketplace opportunities stemming from the burgeoning growth of oncogenomics. Oncogenomics: The Future of Cancer Care offers insightful evaluation of the following key challenges to achieving this goal and examines current approaches to addressing these issues:
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||